Melanoma / / edited by Ahmed Lasfar, Karine Cohen-Solal.
Although melanoma represents a limited number of cutaneous cancers each year, it remains a significant public health crisis because the metastatic disease is associated with poor survival. The incidence of the disease has increased 200% since 1973 and the median age at diagnosis is 40 years, making...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | London : : IntechOpen,, 2021. |
Year of Publication: | 2021 |
Language: | English |
Physical Description: | 1 online resource (148 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993603435204498 |
---|---|
ctrlnum |
(CKB)5400000000044449 (NjHacI)995400000000044449 (EXLCZ)995400000000044449 |
collection |
bib_alma |
record_format |
marc |
spelling |
Melanoma / edited by Ahmed Lasfar, Karine Cohen-Solal. London : IntechOpen, 2021. 1 online resource (148 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on publisher supplied metadata and other sources. Although melanoma represents a limited number of cutaneous cancers each year, it remains a significant public health crisis because the metastatic disease is associated with poor survival. The incidence of the disease has increased 200% since 1973 and the median age at diagnosis is 40 years, making it one of the most significant cancers responsible for productive years of life lost. Fortunately, there has been unprecedented progress in the treatment of advanced melanoma, largely through advances in understanding how to manipulate immune responses and target selective genetic mutations in melanoma patients. Clinical benefits to patients with advanced melanoma have been nevertheless limited by the development of innate and acquired drug resistance, and numerous efforts are focusing on the elucidation of these mechanisms. Combination strategies are being actively investigated to overcome drug resistance, by awakening existing anti-tumor mechanisms disabled by a cancer-promoting microenvironment. This book explores the advances and challenges associated with melanoma today, particularly those related to its diagnosis and management. It also proposes new avenues for therapeutic opportunities based on sustained research efforts and ever-growing technological advances. This is a relevant source of knowledge, very useful for researchers, medical doctors, health providers and all individuals interested in learning more about this devastating disease. 1. Introductory Chapter: Melanoma and Therapeutic Perspectives -- 2. Uveal Melanoma -- 3. Ocular Melanoma -- 4. Anorectal Melanoma -- 5. Mucosal Melanoma of the Head and Neck: From Diagnosis to Treatment -- 6. The Role of the Meiotic Component in Reproduction of B-RAF-Mutated Melanoma: A Review and "Brainstorming" Session -- 7. Role of RUNX2 in Melanoma: A New Player in Tumor Progression and Resistance to Therapy. Melanoma. 1-83880-880-9 Lasfar, Ahmed, editor. Cohen-Solal, Karine, editor. |
language |
English |
format |
eBook |
author2 |
Lasfar, Ahmed, Cohen-Solal, Karine, |
author_facet |
Lasfar, Ahmed, Cohen-Solal, Karine, |
author2_variant |
a l al k c s kcs |
author2_role |
TeilnehmendeR TeilnehmendeR |
title |
Melanoma / |
spellingShingle |
Melanoma / 1. Introductory Chapter: Melanoma and Therapeutic Perspectives -- 2. Uveal Melanoma -- 3. Ocular Melanoma -- 4. Anorectal Melanoma -- 5. Mucosal Melanoma of the Head and Neck: From Diagnosis to Treatment -- 6. The Role of the Meiotic Component in Reproduction of B-RAF-Mutated Melanoma: A Review and "Brainstorming" Session -- 7. Role of RUNX2 in Melanoma: A New Player in Tumor Progression and Resistance to Therapy. |
title_full |
Melanoma / edited by Ahmed Lasfar, Karine Cohen-Solal. |
title_fullStr |
Melanoma / edited by Ahmed Lasfar, Karine Cohen-Solal. |
title_full_unstemmed |
Melanoma / edited by Ahmed Lasfar, Karine Cohen-Solal. |
title_auth |
Melanoma / |
title_new |
Melanoma / |
title_sort |
melanoma / |
publisher |
IntechOpen, |
publishDate |
2021 |
physical |
1 online resource (148 pages) |
contents |
1. Introductory Chapter: Melanoma and Therapeutic Perspectives -- 2. Uveal Melanoma -- 3. Ocular Melanoma -- 4. Anorectal Melanoma -- 5. Mucosal Melanoma of the Head and Neck: From Diagnosis to Treatment -- 6. The Role of the Meiotic Component in Reproduction of B-RAF-Mutated Melanoma: A Review and "Brainstorming" Session -- 7. Role of RUNX2 in Melanoma: A New Player in Tumor Progression and Resistance to Therapy. |
isbn |
1-83880-880-9 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC280 |
callnumber-sort |
RC 3280 M37 M453 42021 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
616 - Diseases |
dewey-full |
616.99477 |
dewey-sort |
3616.99477 |
dewey-raw |
616.99477 |
dewey-search |
616.99477 |
work_keys_str_mv |
AT lasfarahmed melanoma AT cohensolalkarine melanoma |
status_str |
n |
ids_txt_mv |
(CKB)5400000000044449 (NjHacI)995400000000044449 (EXLCZ)995400000000044449 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Melanoma / |
author2_original_writing_str_mv |
noLinkedField noLinkedField |
_version_ |
1796653209560809472 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02792nam a2200301 i 4500</leader><controlfield tag="001">993603435204498</controlfield><controlfield tag="005">20230626172755.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230626s2021 enk o 000 0 eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000044449</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995400000000044449</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000044449</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC280.M37</subfield><subfield code="b">.M453 2021</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.99477</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Melanoma /</subfield><subfield code="c">edited by Ahmed Lasfar, Karine Cohen-Solal.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London :</subfield><subfield code="b">IntechOpen,</subfield><subfield code="c">2021.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (148 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Although melanoma represents a limited number of cutaneous cancers each year, it remains a significant public health crisis because the metastatic disease is associated with poor survival. The incidence of the disease has increased 200% since 1973 and the median age at diagnosis is 40 years, making it one of the most significant cancers responsible for productive years of life lost. Fortunately, there has been unprecedented progress in the treatment of advanced melanoma, largely through advances in understanding how to manipulate immune responses and target selective genetic mutations in melanoma patients. Clinical benefits to patients with advanced melanoma have been nevertheless limited by the development of innate and acquired drug resistance, and numerous efforts are focusing on the elucidation of these mechanisms. Combination strategies are being actively investigated to overcome drug resistance, by awakening existing anti-tumor mechanisms disabled by a cancer-promoting microenvironment. This book explores the advances and challenges associated with melanoma today, particularly those related to its diagnosis and management. It also proposes new avenues for therapeutic opportunities based on sustained research efforts and ever-growing technological advances. This is a relevant source of knowledge, very useful for researchers, medical doctors, health providers and all individuals interested in learning more about this devastating disease.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">1. Introductory Chapter: Melanoma and Therapeutic Perspectives -- 2. Uveal Melanoma -- 3. Ocular Melanoma -- 4. Anorectal Melanoma -- 5. Mucosal Melanoma of the Head and Neck: From Diagnosis to Treatment -- 6. The Role of the Meiotic Component in Reproduction of B-RAF-Mutated Melanoma: A Review and "Brainstorming" Session -- 7. Role of RUNX2 in Melanoma: A New Player in Tumor Progression and Resistance to Therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Melanoma.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">1-83880-880-9</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lasfar, Ahmed,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cohen-Solal, Karine,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-07-06 03:21:46 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5351672150004498&Force_direct=true</subfield><subfield code="Z">5351672150004498</subfield><subfield code="b">Available</subfield><subfield code="8">5351672150004498</subfield></datafield></record></collection> |